Welcome to the all-new BIO.org! BIO.org is now your one-stop-shop for everything BIO, from information and resources on our advocacy and policy work, to everything you need to know about BIO events.  For the first time, under the same “roof,” we have you covered from savings on critical items…

Writing for Morning Consult, BIO’s Jim Greenwood discusses the challenges of developing novel antibiotics and highlights the urgent need for policies that incentivize innovators to produce new ones. “The reason why so few antibiotics are being developed is simple – the market is broken. Estimates…

On behalf of the team at BIO, we send our deepest condolences to the family of Dr. John Holaday who tragically passed away. Dr. Holaday’s career was nothing short of inspiring. After earning his Ph.D. from the University of California, San Francisco School of Medicine, he served at the Walter Reed…

On Tuesday, October 8, BIO formally announced that its President and CEO Jim Greenwood would be stepping down from the world's largest biotechnology organization in January 2021. In a letter to BIO staff, Greenwood reflected on his rise to BIO and the accomplishments the organization has achieved…

BIO’s Jim Greenwood joined CSPAN’s Washington Journal for a conversation about drug pricing, the latest proposals being considered on Capitol Hill, the need to sustain biomedical innovation, and ways to ensure patients have access to the medicines they need with out-of-pocket costs they can afford…

BIO is out with a new whiteboard video that explores why more and more patients are facing higher costs when they go to the pharmacy to buy their prescription drugs. See how rebates and discounts within the drug cost ecosystem are often not used by insurers to lower patients’ out-of-pocket drug…

As countries around the world continue to move towards achieving their Sustainable Development Goals, agricultural biotechnology, including genome editing, has become an increasingly critical tool to address food security and environment targets. Over the past year, members of the World Trade…

In a piece for Morning Consult, BIO’s Jim Greenwood writes that while CAR-T cell therapies are changing the way we treat patients with some types of cancer, policies being considered in Washington could delay access to care for individuals covered under Medicare. “While CAR-T therapies represent a…

As BIO’s President and CEO, who proudly represented the Philadelphia suburbs in Congress for 12 years, I am delighted to welcome you to the city I love for the 2019 BIO International Convention – our industry’s largest annual gathering. Philadelphia was the very first capital of the United States…

Just moments after it was announced the FDA had approved a new treatment for spinal muscular atrophy, Dr. Peter Bach was warning about a “break down” in the U.S. drug pricing system. It’s unfortunate Dr. Bach would respond to the discovery of a miracle cure for a fatal disease with such doom and…